Log in

Frequency Therapeutics Earnings Date, Estimates & History

+0.08 (+0.31 %)
(As of 11/25/2020 12:00 AM ET)
Today's Range
Now: $26.05
50-Day Range
MA: $22.91
52-Week Range
Now: $26.05
Volume223,492 shs
Average Volume179,488 shs
Market Capitalization$878.80 million
P/E RatioN/A
Dividend YieldN/A


Frequency Therapeutics (NASDAQ:FREQ) Earnings Information

Frequency Therapeutics last released its earnings results on November 15th, 2020. The reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.12. The company had revenue of $11.25 million for the quarter, compared to analyst estimates of $7 million. Frequency Therapeutics has generated ($2.29) earnings per share over the last year. Frequency Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 25th, 2021 based off prior year's report dates.

Frequency Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Frequency Therapeutics (NASDAQ:FREQ) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20201($0.19)($0.19)($0.19)
Q3 20201($0.23)($0.23)($0.23)
Q4 20201($0.13)($0.13)($0.13)

Frequency Therapeutics (NASDAQ FREQ) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
11/15/20209/30/2020($0.28)($0.16)($0.16)$7.00 million$11.25 millionN/A
8/12/20206/30/2020($0.19)($0.19)($0.19)$7.00 million$8.52 millionN/A
5/14/20203/31/2020($0.17)($0.16)($0.16)$7.26 millionN/A
3/26/202012/31/2019$0.10($0.19)($0.19)$4.71 millionN/A
11/18/2019Q3 2019($0.68)($0.73)($0.73)$24.24 millionN/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.